GlassScriptPhysician profile
E John R Samuel
NPI 1801862156
$4,457.73
in general payments reported to CMS, 2019-2025
24 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $531 · 2021: $723 · 2022: $411 · 2023: $315 · 2024: $743 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,483 · Travel and Lodging: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.00 |
| Travel and Lodging | $219.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $867.40 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $726.11 | 2019-2025 | |
| Amarin Pharma, INC. | $473.21 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $339.76 | 2019-2024 | Xarelto |
| Medtronic, INC. | $305.10 | 2024 | Reveal Linq, Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.24 | 2019-2021 | |
| Lilly USA, LLC | $194.33 | 2019-2022 | |
| Pfizer INC. | $190.18 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $177.29 | 2020-2021 | |
| Novo Nordisk INC | $167.49 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $151.86 | 2021-2023 | Verquvo |
| Impulse Dynamics (USA) INC. | $120.16 | 2023-2024 | Optimizer, Optimizer |
| Esperion Therapeutics, INC. | $70.63 | 2020-2023 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $67.50 | 2019 | |
| Althera Pharmaceuticals LLC | $62.61 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $59.69 | 2022 | |
| Sanofi-Aventis U.S. LLC | $41.35 | 2019-2022 | |
| Biosense Webster, INC. | $38.10 | 2025 | Carto 3 |
| Kowa Pharmaceuticals America, INC. | $30.12 | 2019-2020 | |
| Abbott Laboratories | $22.37 | 2021 | |
| Cleerly, INC. | $18.83 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Astrazeneca Pharmaceuticals LP | $17.34 | 2023 | Farxiga |
| Agepha Pharma Fz LLC | $16.43 | 2025 | Lodoco |
| Arbor Pharmaceuticals, INC. | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw E John Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.